10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2026)

10x Genomics has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $198.0 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 1.3% year-over-year to $198.0 million; the TTM figure through Jun 2026 stood at $198.0 million (down 1.3% YoY), while the FY2025 annual figure was $238.6 million, up 17.25% from the prior year.
• Total Non-Current Liabilities came in at $198.0 million for Q2 2026 at 10x Genomics, up from $195.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $238.6 million in Q4 2025 to a low of $188.0 million in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is $206.2 million, with a median of $202.3 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities grew 18.01% in 2022 and slipped 10.02% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $220.3 million in 2022, then slipped by 0.2% to $219.8 million in 2023, then slipped by 7.44% to $203.5 million in 2024, then advanced by 17.25% to $238.6 million in 2025, then slipped by 17.02% to $198.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $198.0 million in Q2 2026, $195.0 million in Q1 2026, and $238.6 million in Q4 2025.